JP2018512160A5 - - Google Patents

Info

Publication number

JP2018512160A5

JP2018512160A5 JP2017553970A JP2017553970A JP2018512160A5 JP 2018512160 A5 JP2018512160 A5 JP 2018512160A5 JP 2017553970 A JP2017553970 A JP 2017553970A JP 2017553970 A JP2017553970 A JP 2017553970A JP 2018512160 A5 JP2018512160 A5 JP 2018512160A5

Authority

JP

Japan

Prior art keywords

sample

biomarkers

classifier biomarkers

item

subtype

Prior art date

2016-04-14

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000090 biomarker Substances 0.000 claims description 194
• 238000000034 method Methods 0.000 claims description 102
• 230000014509 gene expression Effects 0.000 claims description 51
• 238000009396 hybridization Methods 0.000 claims description 43
• 208000009956 adenocarcinoma Diseases 0.000 claims description 17
• 210000004072 lung Anatomy 0.000 claims description 13
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 12
• 238000010240 RT-PCR analysis Methods 0.000 claims description 12
• 201000005202 lung cancer Diseases 0.000 claims description 12
• 208000020816 lung neoplasm Diseases 0.000 claims description 12
• 201000002120 neuroendocrine carcinoma Diseases 0.000 claims description 12
• 206010041823 squamous cell carcinoma Diseases 0.000 claims description 12
• 108020004707 nucleic acids Proteins 0.000 claims description 11
• 150000007523 nucleic acids Chemical class 0.000 claims description 11
• 102000039446 nucleic acids Human genes 0.000 claims description 11
• 108091034117 Oligonucleotide Proteins 0.000 claims description 10
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 10
• 238000004458 analytical method Methods 0.000 claims description 10
• 230000000295 complement effect Effects 0.000 claims description 9
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 8
• 201000010099 disease Diseases 0.000 claims description 8
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
• 238000012896 Statistical algorithm Methods 0.000 claims description 6
• 238000010195 expression analysis Methods 0.000 claims description 5
• 239000012188 paraffin wax Substances 0.000 claims description 5
• 230000000877 morphologic effect Effects 0.000 claims description 4
• 238000003559 RNA-seq method Methods 0.000 claims description 3
• 201000009030 Carcinoma Diseases 0.000 claims description 2
• 208000002458 carcinoid tumor Diseases 0.000 claims description 2
• 208000000649 small cell carcinoma Diseases 0.000 claims description 2
• 230000004083 survival effect Effects 0.000 claims description 2
• 238000004519 manufacturing process Methods 0.000 claims 1
• 230000000955 neuroendocrine Effects 0.000 claims 1
• 239000000523 sample Substances 0.000 description 58
• 230000002757 inflammatory effect Effects 0.000 description 7
• 230000002062 proliferating effect Effects 0.000 description 7
• 230000000241 respiratory effect Effects 0.000 description 7
• 239000002299 complementary DNA Substances 0.000 description 5
• 108020004999 messenger RNA Proteins 0.000 description 2
• 238000003556 assay Methods 0.000 description 1
• 239000012520 frozen sample Substances 0.000 description 1
• 210000005265 lung cell Anatomy 0.000 description 1